![]() |
CiteULike | ![]() |
BigRedBall's CiteULike | ![]() |
![]() |
|
![]() |
Register | ![]() |
Log in | ![]() |
Taking TRIPS to India -- Novartis, Patent Law, and Access to Medicines |
Reviews
[Write a review of this article]
Find related articles from these CiteULike users
Find related articles with these CiteULike tags
Posting History
AbstractIn Aug and Sep 2006, patients with cancer, lawyers for patient advocacy groups, and representatives of nongovernmental organizations converged on the offices of Novartis in Mumbai, India, to protest the company's efforts to obtain an Indian patent on Gleevec, the company's brand-name version of imatinib mesylate. The protesters also decried the drug's high price: Novartis sells it in India (where only 5% of people have private health insurance) for $26,000 per year; generic-drug manufacturers offer the drug at less than one tenth that price.
BibTeX record
RIS record